Roffman Miller Associates’s Medtronic MDT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$429K Sell
5,484
-311
-5% -$25.1K 0.02% 83
2026
Q1
$502K Sell
5,795
-2,522
-30% -$242K 0.03% 80
2025
Q4
$799K Sell
8,317
-861
-9% -$83.6K 0.04% 75
2025
Q3
$874K Sell
9,178
-6,127
-40% -$563K 0.05% 74
2025
Q2
$1.33M Sell
15,305
-3,925
-20% -$333K 0.08% 63
2025
Q1
$1.73M Sell
19,230
-11,432
-37% -$1.02M 0.11% 61
2024
Q4
$2.45M Sell
30,662
-13,331
-30% -$1.15M 0.15% 57
2024
Q3
$3.96M Sell
43,993
-185,865
-81% -$15.6M 0.24% 55
2024
Q2
$18.1M Sell
229,858
-7,668
-3% -$629K 1.19% 34
2024
Q1
$20.7M Sell
237,526
-4,681
-2% -$399K 1.38% 31
2023
Q4
$20M Sell
242,207
-25,144
-9% -$1.92M 1.42% 31
2023
Q3
$20.9M Sell
267,351
-3,771
-1% -$316K 1.66% 25
2023
Q2
$23.9M Sell
271,122
-1,749
-0.6% -$151K 1.8% 25
2023
Q1
$22M Sell
272,871
-5,633
-2% -$459K 1.75% 28
2022
Q4
$21.6M Buy
278,504
+875
+0.3% +$70.9K 1.78% 25
2022
Q3
$22.4M Buy
277,629
+4,180
+2% +$376K 2.05% 19
2022
Q2
$24.5M Buy
273,449
+2,772
+1% +$281K 2.12% 19
2022
Q1
$30M Buy
270,677
+422
+0.2% +$44.6K 2.23% 19
2021
Q4
$28M Buy
270,255
+1,991
+0.7% +$231K 1.89% 21
2021
Q3
$33.6M Sell
268,264
-170,028
-39% -$22M 2.5% 16
2021
Q2
$32.9M Buy
438,292
+16,369
+4% +$2.06M 2.49% 16
2021
Q1
$31.2M Buy
421,923
+59,029
+16% +$6.92M 2.59% 15
2020
Q4
$30.6M Buy
362,894
+101,223
+39% +$11.1M 2.65% 16
2020
Q3
$27.2M Buy
261,671
+1,469
+0.6% +$148K 2.63% 17
2020
Q2
$23.9M Buy
260,202
+519
+0.2% +$49.8K 2.37% 18
2020
Q1
$23.4M Buy
259,683
+1,615
+0.6% +$172K 2.93% 13
2019
Q4
$29.3M Sell
258,068
-1,381
-0.5% -$152K 2.93% 13
2019
Q3
$28.2M Sell
259,449
-4,700
-2% -$490K 2.95% 14
2019
Q2
$25.7M Buy
264,149
+7,940
+3% +$725K 2.76% 16
2019
Q1
$23.3M Buy
256,209
+9,289
+4% +$831K 2.66% 18
2018
Q4
$22.5M Sell
246,920
-2,251
-0.9% -$210K 2.93% 13
2018
Q3
$24.5M Sell
249,171
-1,008
-0.4% -$93.2K 2.72% 15
2018
Q2
$21.4M Buy
250,179
+708
+0.3% +$59.1K 2.62% 18
2018
Q1
$20M Buy
249,471
+6,139
+3% +$506K 2.54% 19
2017
Q4
$19.6M Buy
243,332
+5,601
+2% +$449K 2.42% 19
2017
Q3
$18.5M Buy
237,731
+6,929
+3% +$575K 2.44% 18
2017
Q2
$20.5M Buy
230,802
+7,253
+3% +$612K 2.81% 14
2017
Q1
$18M Buy
223,549
+3,180
+1% +$248K 2.55% 16
2016
Q4
$15.7M Buy
220,369
+19,711
+10% +$1.55M 2.37% 20
2016
Q3
$17.3M Buy
200,658
+1,530
+0.8% +$133K 2.81% 11
2016
Q2
$17.3M Buy
199,128
+9,599
+5% +$776K 2.83% 10
2016
Q1
$14.2M Buy
189,529
+9,934
+6% +$748K 2.44% 17
2015
Q4
$13.8M Buy
179,595
+7,108
+4% +$535K 2.53% 16
2015
Q3
$11.5M Buy
172,487
+6,396
+4% +$471K 2.26% 17
2015
Q2
$12.3M Buy
166,091
+5,508
+3% +$421K 2.34% 17
2015
Q1
$12.5M Buy
160,583
+3,010
+2% +$228K 2.4% 16
2014
Q4
$11.4M Buy
157,573
+1,683
+1% +$117K 2.21% 18
2014
Q3
$9.66M Buy
155,890
+6,513
+4% +$414K 1.98% 26
2014
Q2
$9.52M Buy
149,377
+12,825
+9% +$779K 2.01% 26
2014
Q1
$8.4M Buy
136,552
+48,200
+55% +$2.81M 1.87% 26
2013
Q4
$5.07M Buy
88,352
+426
+0.5% +$24.2K 1.17% 39
2013
Q3
$4.68M Buy
87,926
+5,555
+7% +$299K 1.18% 39
2013
Q2
$4.24M Buy
+82,371
New +$4.07M 1.13% 40

Other funds holding MDT

Roffman Miller Associates's MDT Position: Q2 2026 in Review

Roffman Miller Associates reduced its Medtronic (MDT) stake by 5.4% in Q2 2026, selling an estimated $25.1K and leaving 5,484 shares worth $429K. The position accounts for 0.02% of the portfolio, ranked #83.

Roffman Miller Associates first reported a position in MDT in Q2 2013 and has held it in 53 quarters since. The position peaked at $33.6M in Q3 2021. 673 funds tracked by Wall St. Rank hold MDT as of Q2 2026.

  • Roffman Miller Associates held 5,484 shares of Medtronic worth $429K as of Q2 2026.
  • Roffman Miller Associates sold 311 Medtronic shares in Q2 2026, an estimated $25.1K.
  • Medtronic made up 0.02% of Roffman Miller Associates's portfolio in Q2 2026, its #83 holding.
  • Roffman Miller Associates first reported a position in Medtronic in Q2 2013 and has held it in 53 quarters since.
  • Roffman Miller Associates's Medtronic position peaked at $33.6M in Q3 2021.
  • 673 funds tracked by Wall St. Rank held Medtronic as of Q2 2026.

Based on Roffman Miller Associates's 13F filing for Q2 2026, filed 13 Jul 2026.